StockNews.AI
FLGT
StockNews.AI
83 days

INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation Of Fulgent Genetics, Inc. (NASDAQ: FLGT) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm

1. Edelson Lechtzin LLP is investigating Fulgent for securities law violations. 2. Allegations involve misleading business information to investors. 3. Fulgent received a DOJ civil investigative demand related to COVID-19 claims. 4. Following the disclosure, FLGT's stock fell by 2.61% within two days. 5. The investigation could increase volatility concerning Fulgent's stock.

4m saved
Insight
Article

FAQ

Why Bearish?

The investigation and allegations of misleading information typically lead to price declines. Historical precedents show declines in stocks facing similar legal scrutiny.

How important is it?

Given ongoing investigations into potential securities violations, investor confidence can be shaken, impacting FLGT's share price significantly.

Why Short Term?

The immediate impact is likely due to current investor sentiment and volatility. Swift market reactions to legal concerns can alter stock performance quickly.

Related Companies

PTGXNTRAABTLH
NEWTOWN, Pa., May 28, 2025 (GLOBE NEWSWIRE) -- Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving Fulgent Genetics, Inc. (“Fulgent”) (NASDAQ: FLGT), resulting from allegations of providing potentially misleading business information to the investing public. If you have non-public information that could assist in the Fulgent investigation, or if you are a Fulgent investor who suffered a loss and would like to learn more, you can provide your information HERE. You can also contact attorney Eric Lechtzin of Edelson Lechtzin LLP by calling 844-563-5550 or via e-mail at elechtzin@edelson-law.com. THE COMPANY: Fulgent is a biotechnology company specializing in diagnostic and genetic laboratory testing services. It also develops pharmaceutical treatments for various diseases and medical conditions. THE ALLEGED WRONGDOING: On February 28, 2025, Fulgent disclosed in its annual report filed with the U.S. Securities and Exchange Commission that it had received a civil investigative demand from the U.S. Department of Justice. The demand relates to potential false claims submitted under the federal COVID-19 testing program for uninsured individuals. Following this disclosure, Fulgent’s stock price declined by $0.41 per share, or approximately 2.61%, over the next two trading days, closing at $15.28 per share on March 3, 2025. ABOUT EDELSON LECHTZIN LLP: Edelson Lechtzin LLP is a national class action law firm with offices in Pennsylvania and California. In addition to cases involving securities and investment fraud, our lawyers focus on class cases alleging violations of the federal antitrust laws, employee benefit plans under ERISA, wage theft, data security, and consumer fraud. For more information, please contact: Marc H. Edelson, Esq.Eric Lechtzin, Esq.EDELSON LECHTZIN LLP411 S. State Street, Suite N-300Newtown, PA 18940Phone: 844-696-7492 or 215-867-2399 ext. 1 Email: medelson@edelson-law.com Email: elechtzin@edelson-law.com   Web: www.edelson-law.com This press release may be considered Attorney Advertising in some jurisdictions. No class has been certified in this case, so you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. Your ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Related News